To view this email as a web page, click here.
July 8, 2019
 
Lipid-lowering drugs, lower DR risk may go hand in hand
image description here Learn how patients with type 2 diabetes benefited from lipid-lowering medications in a large retrospective cohort study.
Read more
ADVERTISEMENT
 
Anti-VEGF expansion treats all DR stages
image description here See what an expanded indication for aflibercept means for the treatment of patients with diabetic retinopathy.
Find out
ADVERTISEMENT
 
Cataract surgery in patients with diabetes: No time like the present
image description here Here’s why cataract surgery should not be delayed based on the HbA1c levels in patients with diabetic eye disease.
Learn more
ADVERTISEMENT
 
ADVERTISEMENT
What questions do you have about retinal disease in patients with diabetes? Discuss them over dinner at a free program in Chicago, July 27, brought to you by Ophthalmology Times and Regeneron. Save your seat now.
 
RELATED ARTICLES
 
What strict adherence means for successful PDR results
Image-reading accuracy Increases with deep-learning DR algorithms
Determining DR progression: Much work still needs to be done
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.